Yui Shimizu

1.2k citations
18 papers · 490 indexed · h-index 9
Topics
IgG4-Related and Inflammatory Diseases (9 papers)Neuroendocrine Tumor Research Advances (4 papers)Gastrointestinal disorders and treatments (4 papers)
Partner nations
Japan

In The Last Decade

Yui Shimizu

18 papers receiving 478 citations

Peers

Yui Shimizu
Comparison fields: 5 of 49
  • Rheumatology 414
  • Epidemiology 314
  • Surgery 268
  • Molecular Biology 51
  • Immunology 47
Replace Mikiko Obara with:
Mikiko Obara Japan
A. Grados France
Maki Inai Japan
Faiz Karim Netherlands
Gaia Mancuso Italy
Ana D. Fernandes United States
Liyang Gu China
Shaozhe Cai China
Françoise Fortenfant France
Marine Fauny France
Yui Shimizu relative to Mikiko Obara Japan Mikiko Obara's profile →
Citations per field
00.5×1.5×2.5×
Mikiko Obara · 1×
Citations per year

Countries citing papers authored by Yui Shimizu

Since Specialization
Citations

This map shows the geographic impact of Yui Shimizu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yui Shimizu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yui Shimizu more than expected).

Fields of papers citing papers by Yui Shimizu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yui Shimizu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yui Shimizu. The network helps show where Yui Shimizu may publish in the future.

Co-authorship network of co-authors of Yui Shimizu

This figure shows the co-authorship network connecting the top 25 collaborators of Yui Shimizu. A scholar is included among the top collaborators of Yui Shimizu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yui Shimizu. Yui Shimizu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
#WorkIndexed citations
1 9
2 1
3 1
4 3
5 10
6 6
7 4
8 17
9 8
10 14
11 12
12 4
13 11
14 7
15 11
16
[Clinical efficacy of adalimumab for a postoperative marginal ulcer in gastrointestinal Behçet disease].
4
17 175
18 193

About Yui Shimizu

Yui Shimizu is a scholar working on Rheumatology, Surgery and Pathology and Forensic Medicine, having authored 18 papers that have together received 490 indexed citations. Recurring topics across this work include IgG4-Related and Inflammatory Diseases (9 papers), Neuroendocrine Tumor Research Advances (4 papers) and Gastrointestinal disorders and treatments (4 papers). The work is most often cited by research in Rheumatology (414 citations), Epidemiology (314 citations) and Surgery (268 citations). Yui Shimizu has collaborated with scholars based in Japan. Frequent co-authors include Yasuyoshi Naishiro, Hidetaka Yajima, Chisako Suzuki, Yasuhisa Shinomura, Motohisa Yamamoto, Kohzoh Imai, Tetsuya Tabeya, Keisuke Ishigami, Hiroki Takahashi and Mikiko Obara. Their work appears in journals such as The Journal of Immunology, Cancer Research and Biochemical and Biophysical Research Communications.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026